Although we observed that COUP-TFI may be involved in tamoxifen resistance of breast cancers; in contrast, Riggs et al. have proposed that high expression of COUP-TFII could be associated with increased tamoxifen sensitivity in breast cancer cells. This evidence concerns the gene NR2F2 and breast carcinoma.